A moderately malignant neoplasm composed of primitive neuroectodermal cells dispersed in myxomatous or fibrous stroma intermixed with mature ganglion cells. It may undergo transformation into a neuroblastoma. It arises from the sympathetic trunk or less frequently from the adrenal medulla, cerebral cortex, and other locations. Cervical ganglioneuroblastomas may be associated with HORNER SYNDROME and the tumor may occasionally secrete vasoactive intestinal peptide, resulting in chronic diarrhea.
A benign neoplasm that usually arises from the sympathetic trunk in the mediastinum. Histologic features include spindle cell proliferation (resembling a neurofibroma) and the presence of large ganglion cells. The tumor may present clinically with HORNER SYNDROME or diarrhea due to ectopic production of vasoactive intestinal peptide. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p966)
Abdominal neoplasms refer to abnormal growths or tumors occurring within the abdominal cavity, which can be benign or malignant, and affect various organs such as the pancreas, liver, kidneys, or intestines.
Neoplasms composed of neuroepithelial cells, which have the capacity to differentiate into NEURONS, oligodendrocytes, and ASTROCYTES. The majority of craniospinal tumors are of neuroepithelial origin. (From Dev Biol 1998 Aug 1;200(1):1-5)
Neoplasms which arise from peripheral nerve tissue. This includes NEUROFIBROMAS; SCHWANNOMAS; GRANULAR CELL TUMORS; and malignant peripheral NERVE SHEATH NEOPLASMS. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp1750-1)
Tumors or cancer of the ADRENAL GLANDS.
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)

Results of surgery for a compound adrenal tumor consisting of pheochromocytoma and ganglioneuroblastoma in an adult: 5-year follow-up. (1/34)

A rare, compound adrenal tumor consisting of ganglioneuroblastoma and pheochromocytoma was completely resected in an adult woman. Most of the tumor was occupied by the ganglioneuroblastoma component. This ganglioneuroblastoma was an intermixed tumor, which is known to have a favorable prognosis in children. Based on the lack of spread, the resectability of the tumor, and the histology of the ganglioneuroblastoma, no adjuvant therapy was employed. There was no evidence of recurrence at the 5-year follow-up. This suggests that adjuvant therapy may not be necessary in these compound tumors.  (+info)

Expression of the HMGI(Y) gene products in human neuroblastic tumours correlates with differentiation status. (2/34)

HMGI and HMGY are splicing variants of the HMGI(Y) gene and together with HMGI-C, belong to a family of DNA binding proteins involved in maintaining active chromatin conformation and in the regulation of gene transcription. The expression of the HMGI(Y) gene is maximal during embryonic development, declines in adult differentiated tissues and is reactivated in most transformed cells in vitro and in many human cancers in vivo. The HMGI(Y) genomic locus is frequently rearranged in mesenchymal tumours, suggesting a biological role for HMGI(Y) gene products in tumour biology. HMGIs are both target and modulators of retinoic acid activity. In fact, HMGI(Y) gene expression is differentially regulated by retinoic acid in retinoid-sensitive and -resistant neuroblastoma cells, while HMGI-C participates in conferring retinoic acid resistance in some neuroblastoma cells. In this paper we show that HMGI and HMGY isoforms are equally regulated by retinoic acid in neuroblastoma cell lines at both RNA and protein levels. More importantly our immunohistochemical analysis shows that, although HMGI(Y) is expressed in all neuroblastic tumours, consistently higher levels are observed in less differentiated neuroblastomas compared to more differentiated ganglioneuromas, indicating that HMGI(Y) expression should be evaluated as a potential diagnostic and prognostic marker in neuroblastic tumours.  (+info)

The Gem GTP-binding protein promotes morphological differentiation in neuroblastoma. (3/34)

Gem is a small GTP-binding protein within the Ras superfamily whose function has not been determined. We report here that ectopic Gem expression is sufficient to stimulate cell flattening and neurite extension in N1E-115 and SH-SY5Y neuroblastoma cells, suggesting a role for Gem in cytoskeletal rearrangement and/or morphological differentiation of neurons. Consistent with this potential function, in clinical samples of neuroblastoma, Gem protein was most highly expressed within cells which had differentiated to express ganglionic morphology. Gem was also observed in developing trigeminal nerve ganglia in 12.5 day mouse embryos, demonstrating that Gem expression is a property of normal ganglionic development. Although Gem expression is rare in epithelial and hematopoietic cancer cell lines, constitutive Gem levels were detected in several neuroblastoma cell lines and could be further induced as much as 10-fold following treatment with PMA or the acetylcholine muscarinic agonist, carbachol.  (+info)

WAVE3, an actin-polymerization gene, is truncated and inactivated as a result of a constitutional t(1;13)(q21;q12) chromosome translocation in a patient with ganglioneuroblastoma. (4/34)

Neuroblastoma (Nb) is a malignancy of the sympathetic nervous system which affects children in their first decade. It is the most common extra-cranial solid tumor in children with an incidence of approximately 1 in 8-10 000 live births annually and accounts for approximately 10% of all children's cancers. Ganglioneuroblastoma is a relatively benign form of Nb and consists of a mixture of fibrils, mature and maturing ganglion cells, as well as undifferentiated neuroblasts. During routine cytogenetic analysis of patients with different manifestations of neuroblastoma we have identified one patient with ganglioneuroblastoma that carries an apparently balanced t(1:13)(q21:q12) reciprocal translocation. Positional cloning of the translocation breakpoint on chromosome 13 resulted in the mapping of the breakpoint between coding exon 2 and exon 3 of WAVE3, a member of WASP gene family. Although the breakpoint region on chromosome 1 was localized to within 2 kb of genomic sequence, no gene was found to be interrupted on this chromosome. The WAVE3 transcript is mainly expressed in the nervous system and, like all the members of the WASP gene family, WAVE3 is a key element in actin polymerization and cytoskeleton organization. WAVE3, therefore, is important for cell differentiation and motility and its expression is lost in a number of low grade and stage 4S tumors. From analysis of its expression pattern and function, WAVE3 is a candidate tumor suppressor gene, at least in some forms of neuroblastoma.  (+info)

Ganglioneuroblastoma presenting as dilated cardiomyopathy. (5/34)

We report an unusual presentation of ganglioneuroblastoma with features of dilated cardiomyopathy in a 22 month old girl. She was admitted with cardiomegaly; during echocardiography a suspicious abdominal mass was detected by chance. Further imaging studies, including abdominal ultrasonography and spiral computed tomography, revealed a solid mass originating in the right adrenal gland. Metabolic studies and pathological findings were compatible with ganglioneuroblastoma. Following tumour removal and supportive therapy for cardiomyopathy, her clinical condition and laboratory findings improved. Although ganglioneuroblastoma with features of dilated cardiomyopathy is rare, because neurogenic tumours may be involved in its development, measurement of catecholamines in children with dilated cardiomyopathy is strongly recommended.  (+info)

Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. (6/34)

BACKGROUND: Ganglioneuroblastoma, nodular (GNBn) comprises one of the categories of peripheral neuroblastic tumors. All tumors in this category, according to the original International Neuroblastoma Pathology Classification, are classified into an unfavorable histology group. Subsequently, it has been reported that GNBn can be divided into two prognostic subsets, a favorable subset (FS) and an unfavorable subset (US). METHODS: Histology slides from 70 patients who were enrolled in Children's Cancer Group studies 3881 and 3891 and who had a diagnosis of GNBn were reviewed jointly by the members of International Neuroblastoma Pathology Committee (INPC): 1) to confirm the diagnosis of GNBn, 2) to identify the FS and US by applying the same age-linked criteria that were used to distinguish the favorable histology group and unfavorable histology group in conventional neuroblastoma tumors from the neuroblastomatous component of GNBn tumors, and 3) to verify the significant prognostic difference between these two subsets. The patients had been used in a previous study, and survival data for the patients were updated since the time of their last report. RESULTS: The review clarified and illustrated morphologic characteristics of classical GNBn and it variants. The diagnosis of GNBn was confirmed in 67 of 70 patients. There were 22 patients with GNBn in the FS and 45 patients with GNBn in the US. The estimated survival differences between the FS and US patients with GNBn were statistically significant (8-year event free survival rate: 86.1% vs. 32.2%; P = 0.0003; overall survival rate: 90.5% vs. 33.2%; P = 0.0003). CONCLUSIONS: This study confirmed the recently defined prognostic subsets of GNBn. The INPC proposes to modify the International Neuroblastoma Pathology Classification by distinguishing the FS and the US among patients with GNBn tumors.  (+info)

Cerebral ganglioneuroblastoma in a golden retriever dog. (7/34)

An 8-month-old Golden Retriever dog was euthanatized because of a large cerebral mass extending from the right frontal lobe to the thalamus that was composed of both mature and immature neuronal cells. The better differentiated cells had abundant eosinophilic cytoplasm with prominent Nissl substance and were generally positive for neurofilament and variably positive for synaptophysin. The generally smaller and less-differentiated cells were infrequently positive for proliferating cell nuclear antigen and were negative for any neuronal and glial markers. No apparent glial differentiation of the immature tumor cells was detected. Based on morphologic and immunohistochemical features, the diagnosis of cerebral ganglioneuroblastoma was made. This neoplasm is very rare in all species, especially in the central nervous system, and has never been reported previously in this site in a dog.  (+info)

TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance. (8/34)

BACKGROUND: This study was conducted to investigate the prognostic significance and biologic relevance of trkA expression levels in peripheral neuroblastic tumors (pNTs) (i.e., neuroblastoma, ganglioneuroblastoma, and ganglioneuroma). METHODS: Levels of trkA expression from a total of 265 pNTs were determined by quantitative polymerase chain reaction analysis with Genescan software. The results were analyzed according to histopathology (favorable histology [FH] vs. unfavorable histology [UH] according to the International Neuroblastoma Pathology Classification) and MYCN tumor status (amplified vs. nonamplified) along with clinical stage and outcomes of the patients. RESULTS: The levels of trkA expression differed significantly between the group of patients who were alive and well (n = 170 patients) and the group that had progressed or died (n = 95 patients) and between the group that was alive (n = 188 patients) and the group that died (n = 77 patients). However, the trkA expression levels were not independent predictors of clinical outcome when the proportional hazards model contained the known prognostic variables of clinical stage, histopathology, and MYCN status (all tests were done in 196 patients). In the neuroblastoma category (n = 173 tumors), tumors in the FH/nonamplified MYCN subset (n = 112 tumors) expressed higher levels of trkA and showed an age-dependent neuroblastic differentiation: They were classified into either a poorly differentiated subtype (n = 91 tumors; all patients age < 1.5 years at diagnosis) or a differentiating subtype (n = 21 tumors; 57% of patients ages 1.5-5.0 years). Tumors in the UH/amplified MYCN subset (n = 30 tumors) expressed significantly lower levels of trkA and showed very limited neuroblastic differentiation. Tumors in the FH/amplified MYCN subset were very rare (n = 3 tumors) and expressed higher levels of trkA. Tumors in the UH/nonamplified MYCN subset (n = 28 tumors) had trkA levels in a wide range and showed limited neuroblastic differentiation. CONCLUSIONS: For patients with pNTs, levels of trkA expression did not add significant information to prognostic grouping, as defined by the combination of clinical stage, histopathology, and MYCN status. There was a biologically relevant correlation between molecular properties (trkA expression and MYCN status) and histopathologic features of the tumors in the neuroblastoma category.  (+info)

Ganglioneuroblastoma is a rare tumor that arises from the neural crest cells, which are immature cells in the sympathetic nervous system. It typically occurs in children who are younger than 10 years old, with most diagnoses occurring within the first year of life. The tumor can develop anywhere along the sympathetic nervous system but is most commonly found in the adrenal glands (small glands located on top of each kidney) or along the spine.

Ganglioneuroblastoma is a type of neuroblastoma, which is a broader category of tumors that also arise from neural crest cells. Ganglioneuroblastomas are unique within this group because they have a mix of both mature and immature cells. The presence of these more mature cells can make ganglioneuroblastomas less aggressive than other neuroblastomas, although the behavior of the tumor can vary widely depending on factors such as its size, location, and whether it has spread to other parts of the body (metastasized).

Treatment for ganglioneuroblastoma typically involves a combination of surgery, chemotherapy, and radiation therapy. The specific approach will depend on various factors, including the patient's age, overall health, and the stage and aggressiveness of the tumor. With appropriate treatment, many children with ganglioneuroblastoma can achieve long-term survival and even cure.

A ganglioneuroma is a type of benign (noncancerous) tumor that arises from the nerve cells called ganglia in the autonomic nervous system. These tumors typically develop in the abdomen or chest and are most commonly found in children and adolescents, although they can occur at any age.

Ganglioneuromas are composed of mature nerve cells (ganglion cells) and supporting tissue called stroma. They tend to grow slowly and usually do not cause any symptoms unless they become very large or press on nearby organs. In some cases, ganglioneuromas may produce hormones that can cause symptoms such as diarrhea, flushing, or heart palpitations.

While ganglioneuromas are generally benign, there is a small risk that they may become malignant (cancerous) and develop into a type of tumor called a ganglioneuroblastoma or neuroblastoma. For this reason, it is important to monitor these tumors closely and remove them if they grow too large or cause symptoms.

Treatment for ganglioneuromas typically involves surgical removal of the tumor. In some cases, radiation therapy or chemotherapy may also be recommended, particularly if there is a risk of malignant transformation.

Abdominal neoplasms refer to abnormal growths or tumors in the abdomen that can be benign (non-cancerous) or malignant (cancerous). These growths can occur in any of the organs within the abdominal cavity, including the stomach, small intestine, large intestine, liver, pancreas, spleen, and kidneys.

Abdominal neoplasms can cause various symptoms depending on their size, location, and type. Some common symptoms include abdominal pain or discomfort, bloating, changes in bowel habits, unexplained weight loss, fatigue, and fever. In some cases, abdominal neoplasms may not cause any symptoms until they have grown quite large or spread to other parts of the body.

The diagnosis of abdominal neoplasms typically involves a combination of physical exam, medical history, imaging studies such as CT scans or MRIs, and sometimes biopsy to confirm the type of tumor. Treatment options depend on the type, stage, and location of the neoplasm but may include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these approaches.

Neuroepithelial neoplasms are a type of tumor that arises from the neuroepithelium, which is the tissue in the developing embryo that gives rise to the nervous system. These tumors can occur anywhere along the nervous system, including the brain and spinal cord (central nervous system) or the peripheral nerves.

Neuroepithelial neoplasms can be benign or malignant, and they can vary widely in their behavior and prognosis. Some common types of neuroepithelial neoplasms include:

1. Astrocytomas: These are tumors that arise from astrocytes, a type of star-shaped glial cell in the brain. Astrocytomas can be low-grade (slow-growing) or high-grade (fast-growing), and they can occur in different parts of the brain.
2. Oligodendrogliomas: These are tumors that arise from oligodendrocytes, a type of glial cell that provides support and insulation to nerve cells in the brain. Oligodendrogliomas are typically low-grade and slow-growing.
3. Ependymomas: These are tumors that arise from the ependyma, which is the tissue that lines the ventricles (fluid-filled spaces) in the brain and the spinal cord canal. Ependymomas can be benign or malignant, and they can occur in the brain or the spinal cord.
4. Medulloblastomas: These are fast-growing tumors that arise from primitive neuroectodermal cells in the cerebellum (the part of the brain that controls balance and coordination). Medulloblastomas are highly malignant and can spread to other parts of the brain and spinal cord.
5. Glioblastomas: These are the most common and aggressive type of primary brain tumor. They arise from astrocytes and can grow rapidly, invading surrounding brain tissue.

Neuroepithelial neoplasms are typically treated with surgery, radiation therapy, and chemotherapy, depending on the type and location of the tumor. The prognosis varies widely depending on the specific type and stage of the tumor.

Peripheral nervous system (PNS) neoplasms refer to tumors that originate in the peripheral nerves, which are the nerves outside the brain and spinal cord. These tumors can be benign or malignant (cancerous). Benign tumors, such as schwannomas and neurofibromas, grow slowly and do not spread to other parts of the body. Malignant tumors, such as malignant peripheral nerve sheath tumors (MPNSTs), can invade nearby tissues and may metastasize (spread) to other organs.

PNS neoplasms can cause various symptoms depending on their location and size. Common symptoms include pain, weakness, numbness, or tingling in the affected area. In some cases, PNS neoplasms may not cause any symptoms until they become quite large. Treatment options for PNS neoplasms depend on several factors, including the type, size, and location of the tumor, as well as the patient's overall health. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Adrenal gland neoplasms refer to abnormal growths or tumors in the adrenal glands. These glands are located on top of each kidney and are responsible for producing hormones that regulate various bodily functions such as metabolism, blood pressure, and stress response. Adrenal gland neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign adrenal tumors are called adenomas and are usually small and asymptomatic. However, some adenomas may produce excessive amounts of hormones, leading to symptoms such as high blood pressure, weight gain, and mood changes.

Malignant adrenal tumors are called adrenocortical carcinomas and are rare but aggressive cancers that can spread to other parts of the body. Symptoms of adrenocortical carcinoma may include abdominal pain, weight loss, and hormonal imbalances.

It is important to diagnose and treat adrenal gland neoplasms early to prevent complications and improve outcomes. Diagnostic tests may include imaging studies such as CT scans or MRIs, as well as hormone level testing and biopsy. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Neuroblastoma is defined as a type of cancer that develops from immature nerve cells found in the fetal or early postnatal period, called neuroblasts. It typically occurs in infants and young children, with around 90% of cases diagnosed before age five. The tumors often originate in the adrenal glands but can also arise in the neck, chest, abdomen, or spine. Neuroblastoma is characterized by its ability to spread (metastasize) to other parts of the body, including bones, bone marrow, lymph nodes, and skin. The severity and prognosis of neuroblastoma can vary widely, depending on factors such as the patient's age at diagnosis, stage of the disease, and specific genetic features of the tumor.

... is a variant of neuroblastoma that is surrounded by ganglion cells. It can be difficult to diagnose. ... Nodular ganglioneuroblastoma can be divided by prognosis. It is contained within the neuroblastic tumors group, which includes ... "Ganglioneuroblastoma of the cerebellum: neuroimaging and pathological features of a case". Arq Neuropsiquiatr. 65 (2A): 338-40 ... Ganglioneuroma (benign) Ganglioneuroblastoma (intermediate). Neuroblastoma (aggressive) Neuroblastoma Gasparetto EL, Rosemberg ...
Jedynak A. Naul GL (ed.). "Imaging in Ganglioneuroma and Ganglioneuroblastoma". Medscape. WedbMD. Retrieved 6 February 2014. ... It is contained within the neuroblastic tumors group, which includes: Ganglioneuroma (benign), Ganglioneuroblastoma ( ...
The cancers most associated with anti-Hu encephalitis are neuroblastoma and ganglioneuroblastoma. Opsoclonus-myoclonus syndrome ...
4. Naka M, Matsumoto S, Shirai T, Itoh T (1975) Ganglioneuroblastoma associated with malignant mesenchymoma. Cancer 36:1050- ... ganglioneuroblastoma, neuroblastoma, peripheral primitive neuroectodermal tumors - PNET] and one or more mesenchymal neoplastic ...
... but less aggressive tumors composed of more mature neural cells include ganglioneuroblastoma and ganglioneuroma. Neuroblastic ...
... ganglioneuroblastoma, medulloepithelioma, ependymoblastoma, and not otherwise specified PNET. It is similar to medulloblastoma ... ganglioneuroblastoma, medulloepithelioma, ependymoblastoma, and not otherwise specified PNET. The last one encompasses the ...
... two unusual paraneoplastic syndromes occurring concurrently in the same patient with ganglioneuroblastoma". J. Pediatr. Hematol ...
... ganglioneuroblastoma, and ganglion cells with or without schwannian stroma. The rhabdomyoblastic component is derived from ...
While in New Zealand Ngaiire was diagnosed with ganglioneuroblastoma, which manifested as a cancer of her adrenal glands at the ...
... chromosome translocation in a patient with ganglioneuroblastoma". Oncogene. 21 (38): 5967-74. doi:10.1038/sj.onc.1205734. PMID ...
... ganglioneuroblastoma MeSH C04.557.465.625.600.657 - pinealoma MeSH C04.557.465.625.600.725 - retinoblastoma MeSH C04.557. ... ganglioneuroblastoma MeSH C04.557.470.670.657 - pinealoma MeSH C04.557.470.670.725 - retinoblastoma MeSH C04.557.470.700 - ... ganglioneuroblastoma MeSH C04.557.580.625.600.657 - pinealoma MeSH C04.557.580.625.600.725 - retinoblastoma MeSH C04.557. ...
NOS M9490/0 Ganglioneuroma M9490/3 Ganglioneuroblastoma M9491/0 Ganglioneuromatosis M9492/0 Gangliocytoma M9493/0 Dysplastic ...
Hip luxation Hip subluxation Hipo syndrome Hirschsprung disease Hirschsprung disease ganglioneuroblastoma Hirschsprung disease ...
... origins and show a wide pattern of differentiation ranging from benign ganglioneuroma to stroma-rich ganglioneuroblastoma with ...
Ganglioneuroblastoma is a variant of neuroblastoma that is surrounded by ganglion cells. It can be difficult to diagnose. ... Nodular ganglioneuroblastoma can be divided by prognosis. It is contained within the neuroblastic tumors group, which includes ... "Ganglioneuroblastoma of the cerebellum: neuroimaging and pathological features of a case". Arq Neuropsiquiatr. 65 (2A): 338-40 ... Ganglioneuroma (benign) Ganglioneuroblastoma (intermediate). Neuroblastoma (aggressive) Neuroblastoma Gasparetto EL, Rosemberg ...
Ganglioneuroblastoma is an intermediate tumor that arises from nerve tissues. An intermediate tumor is one that is between ... Ganglioneuroblastoma is an intermediate tumor that arises from nerve tissues. An intermediate tumor is one that is between ... A ganglioneuroblastoma may be only in one area or it may be widespread, but it is usually less aggressive than a neuroblastoma ... Ganglioneuroblastoma mostly occurs in children ages 2 to 4 years. The tumor affects boys and girls equally. It occurs rarely in ...
encoded search term (Ganglioneuroma and Ganglioneuroblastoma Imaging) and Ganglioneuroma and Ganglioneuroblastoma Imaging What ... Ganglioneuroma and Ganglioneuroblastoma Imaging Updated: Jul 28, 2020 * Author: Andrzej R Jedynak, MD, MS; Chief Editor: L Gill ... In cases of ganglioneuroblastoma, scintigraphy is not only useful for identifying the primary tumor, but it is also useful for ... Posterior mediastinal ganglioneuroblastoma in an adolescent: A case report and review. Thorac Cancer. 2020 Feb. 11 (2):451-455 ...
Key Words: Surgery, Children, Ganglioneuroblastoma, Computer-assisted, Tumor, Case report Core Tip: The diagnosis and treatment ... The Pitfall of Ganglioneuroblastoma-Nodular Diagnosis: Clinical and Imaging Considerations over a Rare Bifocal Sporadic Case. ... Ganglioneuroblastoma (GNB) derives from primitive neural crest cells of the neuroectoderm[1,2], and its biological behavior and ... Ganglioneuroblastoma (GNB) is a peripheral neuroblastoma (NB) with malignant degree between highly malignant NB and benign ...
Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 ... Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma ... trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. ...
Do you qualify for these Ganglioneuroblastoma studies? Were researching treatments for 2023. ... Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma open to eligible ... Ganglioneuroblastoma clinical trials at UC Davis 2 research studies open to eligible people ... trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. ...
Making a correct diagnosis of ganglioneuroblastoma, nodular is often difficult by biopsy or partial tumor resection, because ... we reached the diagnosis of ganglioneuroblastoma, nodular. Because the nodule demonstrated neuroblastoma, differentiating ... Ganglioneuroblastoma, nodular is defined as a composite tumor of biologically distinct clones. The peripheral neuroblastic ... this category are characterized by the presence of grossly visible neuroblastoma nodules coexisting with ganglioneuroblastoma, ...
Ganglio-neuroblastoma : Gross Pathology. Home "> Endocrine "> Adrenal "> Ganglioneuroblastoma "> Ganglio-neuroblastoma : Gross ... Ganglioneuroblastoma displays a level of maturation and differentiation that is intermediate between the highly aggressive ... The gross appearance of ganglioneuroblastoma is variable and depends upon the subtype and degree of differentiation. They are ...
Shukla, Samriddhi; Saha, Taniya; Rama, Nihar; Acharya, Anusha; Le, Tien; Bian, Fenghua; Donovan, Johnny; Tan, Lin Abigail; Vatner, Ralph; Kalinichenko, Vladimir; Mascia, Anthony; Perentesis, John P; Kalin, Tanya V 2023. Ultra-high dose-rate proton FLASH improves tumor control. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 186 , 109741. Howell, Jackson; Dandoy, Christopher; Wright, Jordan M; Chow, Lionel; El-Sheikh, Ayman; Dole, Mukund; Vatner, Ralph E; Kamian, Kambiz 2022. Extraneural recurrence of an intracranial nongerminomatous germ cell tumor to cervical lymph nodes in a pediatric patient: Case report. Cancer reports (Hoboken, N.J.), 5 8, e1586. Howell, Jackson; Dandoy, Christopher; Wright, Jordan M; Chow, Lionel; El-Sheikh, Ayman; Dole, Mukund; Vatner, Ralph E; Kamian, Kambiz 2022. Extraneural recurrence of an intracranial nongerminomatous germ cell tumor to cervical lymph nodes in a pediatric patient: Case report. Cancer reports ...
IV(a) Neuroblastoma and ganglioneuroblastoma 42 IV(b) Other sympathetic nervous system tumors 50 V Retinoblastoma 60 VI Renal ...
Epidemiology, clinical features and outcomes of ganglioneuroblastoma: An analysis of the National Cancer Database. Bridgett ...
Ganglioneuroblastoma of central nervous system 733926004. *Germinoma of central nervous system 1156833003 ...
A 1-year-3-month old girl presented with ganglioneuroblastoma originating in the neck. On examination, several elastic masses ... Microscopic examination revealed a composite type of ganglioneuroblastoma of the left adrenal tumor and a rosett-fibrillary ... The biopsy revealed that the neck tumor was histlogically ganglioneuroblastoma. The searches by body CT, intravenous ...
A cervicothoracic intramedullary ganglioneuroblastoma presenting with acute quadriparesis. p. 348. Sumit Thakar, Nandita Ghosal ...
... ganglioneuroblastoma, MPNST, neuroblastoma, paraganglioma, gastroenteric cysts * Acquired hypogammaglobulinemia or pure ...
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma ... All newly diagnosed patients with suspected neuroblastoma, suspected ganglioneuroblastoma, or suspected ganglioneuroma/maturing ... diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory ... ganglioneuroblastoma, or ganglioneuroma/ maturing subtype. - Patients may not have received chemotherapy prior to enrollment on ...
Our research addresses a range of the important challenges in the life sciences.. From tackling ecosystem and global change, to innovation in fundamental biosciences for better human, animal, plant and ocean health.. From understanding animal and human behaviour and wellbeing, to developing future synthetic biotechnologies and so driving the UKs bioeconomy.. We are changing the way we understand the fundamental principles of life and the natural world through a series of interrelated research themes.. Underpinning these research themes is a world class state-of-the-art infrastructure for Imaging, Omics and informatics and Responsible research and innovation.. ...
Ganglioneuroblastoma Medicine and Dentistry 100% * Neural Crest Medicine and Dentistry 100% * Anaplastic Lymphoma Kinase ...
Patients must have a diagnosis of neuroblastoma or ganglioneuroblastoma (nodular) verified by tumor pathology analysis or ... or crizotinib and standard therapy may work better in treating younger patients with neuroblastoma or ganglioneuroblastoma. ... and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. ...
Asada Y, Marutsuka K, Mitsukawa T, Kuribayashi T, Taniguchi S, Sumiyoshi A: Ganglioneuroblastoma of the thymus: An adult case ...
... and characterized by night-time hypoventilation and a history of ganglioneuroblastoma. She carried a novel de novo missense ... and characterized by night-time hypoventilation and a history of ganglioneuroblastoma. She carried a novel de novo missense ...
Ganglioneuroblastoma. These tumors are also graded using the INSS. Surgical resection is indicated in those with early disease ... Neuroblastoma and ganglioneuroblastoma. Treatment of mediastinal neuroblastoma is based on the evaluation of a number of risk ... Ganglioneuroblastoma. These tumors are generally less aggressive than neuroblastomas. They are evaluated using the same ... Neuroblastoma exhibits wide local and distant spread and is rapidly fatal, while ganglioneuroblastoma may, in some cases, be ...
Phenotype data for mouse gene Trpm1. Discover Trpm1s significant phenotypes, expression, images, histopathology and more. Data for gene Trpm1 is all freely available for download.
1. Diagnosis: Subjects must have a diagnosis of neuroblastoma or ganglioneuroblastoma (nodular or intermixed) verified by ...
O Ganglioneuroblastoma,O Ganglioneuroma,O Ganglioneuromatosis,O Ganglioside accumulation,O Gangrene,O Gastric arteriovenous ...
Aggarwal, D., Warne, B., Jahun, A. S., Hamilton, W. L., Fieldman, T., du Plessis, L., Hill, V., Blane, B., Watkins, E., Wright, E., Hall, G., Ludden, C., Myers, R., Hosmillo, M., Chaudhry, Y., Pinckert, M. L., Georgana, I., Izuagbe, R., Leek, D., Nsonwu, O., & 30 othersHughes, G. J., Packer, S., Page, A. J., Metaxaki, M., Fuller, S., Weale, G., Holgate, J., Brown, C. A., The Cambridge Covid-19 testing Centre, University of Cambridge Asymptomatic COVID-19 Screening Programme Consortium, The COVID-19 Genomics UK (COG-UK) Consortium, Howes, R., McFarlane, D., Dougan, G., Pybus, O. G., Angelis, D. D., Maxwell, P. H., Peacock, S. J., Weekes, M. P., Illingworth, C., Harrison, E. M., Matheson, N. J., Goodfellow, I. G., Bashton, M., Smith, D. L., Young, G. R., McCann, C. M., Nelson, A., Yew, W. C. & Jones, H., Dec 2022, In: Nature Communications. 13, 1, p. 1-16 16 p., 751.. Research output: Contribution to journal › Article › peer-review ...
Ganglioneuroblastoma: A Rare Tumor in Parapharyngeal Space  Ulu, Şahin; Kınar, Abdullah; Bucak, Abdulkadir (Erciyes Univ Sch ... Background: Ganglioneuroblastoma is a malignant tumor, usually found in the adrenal glands, retroperitoneal ganglions or ... In the head and neck region, Ganglioneuroblastoma is presented as a sub-type ... ...
... this study is enrolling patients and newly diagnosed with suspected neuroblastoma or ganglioneuroblastoma, who are preparing to ...
  • It is contained within the neuroblastic tumors group, which includes: Ganglioneuroma (benign) Ganglioneuroblastoma (intermediate). (wikipedia.org)
  • Ganglioneuroblastoma is a transitional tumor on the intermediate spectrum of disease between ganglioneuromas and neuroblastomas, containing elements of both malignant neuroblastoma and benign ganglioneuroma. (medscape.com)
  • Ganglioneuroblastoma displays a level of maturation and differentiation that is intermediate between the highly aggressive neuroblastoma on one hand and the benign tumor ganglioneuroma at the other end. (webpathology.com)
  • Ganglioneuroblastoma is an intermediate tumor that arises from nerve tissues. (medlineplus.gov)
  • Background: Ganglioneuroblastoma is a malignant tumor, usually found in the adrenal glands, retroperitoneal ganglions or posterior mediastinum. (afsu.edu.tr)
  • Embryonal tumors were described over the years as a collection of histologic entities that includes medulloblastoma and also included medulloepithelioma, CNS neuroblastoma, CNS ganglioneuroblastoma and atypical teratoid/rhabdoid tumor (ATRT) as well as primitive neuroectodermal tumors (PNET). (medscape.com)
  • Based on these characteristics, the tumor was diagnosed as a ganglioneuroblastoma. (springeropen.com)
  • This partially randomized phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. (tuftsmedicalcenter.org)
  • Giving iobenguane I-131 or crizotinib and standard therapy may work better in treating younger patients with neuroblastoma or ganglioneuroblastoma. (tuftsmedicalcenter.org)
  • Subject to certain exclusion criteria, this study is enrolling patients and newly diagnosed with suspected neuroblastoma or ganglioneuroblastoma, who are preparing to undergo a biopsy, a resection or a clinical procedure. (chp.edu)
  • Nodular ganglioneuroblastoma can be divided by prognosis. (wikipedia.org)
  • This axial noncontrast computed tomography image of a ganglioneuroblastoma demonstrates a large, left heterogeneous paraspinal lesion with speckled calcifications that are predominantly peripheral. (medscape.com)
  • Ganglioneuroblastoma is a variant of neuroblastoma that is surrounded by ganglion cells. (wikipedia.org)
  • The gross appearance of ganglioneuroblastoma is variable and depends upon the subtype and degree of differentiation. (webpathology.com)
  • Ganglioneuroblastoma (GNB) is a common pediatric cancer but rarely presents in adults. (anncaserep.com)
  • 7 months later, in January 2015, a month before he turned 3, our youngest son, Anthony was diagnosed with GanglioNeuroblastoma cancer. (mariarosaphotography.com)
  • A ganglioneuroblastoma may be only in one area or it may be widespread, but it is usually less aggressive than a neuroblastoma. (medlineplus.gov)
  • Xiu WL, Liu J, Zhang JL, Su N, Wang FJ, Hao XW, Wang FF, Dong Q. Computer-assisted rescue of the inferior mesenteric artery in a child with a giant ganglioneuroblastoma: A case report. (wjgnet.com)
  • Asada Y, Marutsuka K, Mitsukawa T, Kuribayashi T, Taniguchi S, Sumiyoshi A: Ganglioneuroblastoma of the thymus: An adult case with the syndrome of inappropriate secretion of antidiuretic hormone. (karger.com)
  • Ganglioneuroblastoma mostly occurs in children ages 2 to 4 years. (medlineplus.gov)
  • This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. (vicc.org)
  • Giving iobenguane I-131 or lorlatinib and standard therapy may work better compared to lorlatinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma. (vicc.org)
  • Neuroblastoma or ganglioneuroblastoma of the low-risk group or intermediate-risk group, by NB 2004 protocol and disease staging according to INSS (stages 1-3 and 4s without apmplification of MYCN gene, stage 4 in patients under 18 months of age) and high-risk patients with stages 1-3/4s with amplification of MYCN gene. (who.int)
  • The idea is that a hidden or occult tumor - like a neuroblastoma or ganglioneuroblastoma - triggers the body 's immune system , and the resulting antibodies unintentionally target healthy cells of the nervous system . (osmosis.org)
  • Nodular ganglioneuroblastoma can be divided by prognosis. (wikipedia.org)
  • 19. Histopathology defines prognostic subsets of ganglioneuroblastoma, nodular. (nih.gov)
  • Advanced stages of neuroblastoma and ganglioneuroblastoma are the tumors of neurogenic origin for which surgical resection is not considered as primary treatment. (medscape.com)
  • Central nervous system (CNS) ganglioneuroblastoma is a rare neuroectodermal neoplasm and little is known about its clinical and biological features. (nih.gov)
  • A large posterior mediastinal ganglioneuroblastoma in a child. (gknmhospital.org)
  • Standard therapy includes en-bloc resection, with accompanying radiation therapy (RT) and chemotherapy if complete resection is not possible. (medscape.com)
  • 7. Ganglioneuroblastoma in a newborn with multiple metastases: a case report. (nih.gov)
  • This axial noncontrast computed tomography image of a ganglioneuroblastoma demonstrates a large, left heterogeneous paraspinal lesion with speckled calcifications that are predominantly peripheral. (medscape.com)
  • I encourage you to do a search of the CSN site (entering ganglioneuroblastoma in the search bar at the top of the page). (cancer.org)
  • Neuroblastoma and ganglioneuroblastoma identified at an early stage of disease also may be treated with primary resection. (medscape.com)